Eligibility depends on a comprehensive medical evaluation
FDA procedurally removed it from Category 2 in April 2026 after nominators withdrew their submissions and referred it to the Pharmacy Compounding Advisory Committee, which is scheduled to review it on July 23-24, 2026 for possible inclusion on the approved 503A bulks list
Analytical testing confirms greater than 99.8 % BPC-157 purity and 99.6 % TB-500 purity , assay content verified at 16.04 mg and 13.44 mg respectively, with molecular ion masses identified at 1418 Da and 4962 Da and endotoxin levels below 0.001 EU/mg
Once peptides have been received, it is imperative that they are kept cold and away from light
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements
Blends combine multiple compounds for targeted pathways those are available separately in our Peptide Blends section